+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Repertoire Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 219 Pages
  • November 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5910776
Recent advancements in next-generation sequencing (NGS) technology have paved the way for groundbreaking discoveries in the field of immune repertoire sequencing. This cutting-edge technique, which probes the complementarity-determining regions of B-cell receptors (BCRs) and T-cell receptors (TCRs), is revolutionizing our understanding of the body's defense mechanisms against foreign agents.

Immune Repertoire Sequencing Unveils a World of Opportunities

Immune repertoire sequencing offers an accurate and sensitive platform with minimal invasiveness and sample requirement, providing a dynamic view of the region of interest. Looking ahead, the development of new methods in this field is poised to take center stage, particularly if they can offer more comprehensive sample insights compared to current techniques. The future of immune repertoire sequencing is expected to be dominated by single-cell approaches, offering high-dimensional and in-depth information on smaller populations of interest, including antigen-binding cells.

Market Projections and Regional Dominance

According to recent projections, the global immune repertoire sequencing market is set to grow at an impressive CAGR of 7.3% and is anticipated to reach a valuation of US$ 173.0 million by the end of 2026. In terms of value, North America is poised to emerge as the dominant regional market, with strong growth anticipated in Asia Pacific.

In North America, the United States is expected to lead the way due to a growing demand for immunotherapy in the fight against cancer and infectious diseases. Developments in immune repertoire sequencing methods are expected to play a pivotal role in the progress against cancer, as highlighted by the U.S. National Cancer Institute.

Europe is the second dominant regional market for immune repertoire sequencing, driven by increased healthcare expenditure and government funding. This region boasts a highly competitive landscape, with numerous manufacturers contributing to the market's growth. Additionally, price reductions in genome sequencing have spurred the demand for immune repertoire sequencing.

Asia-Pacific, specifically China and Japan, is witnessing significant growth in the global immune repertoire sequencing market. The adoption of this technology is on the rise, supported by international collaborations and technological advancements in the region. Latin America is experiencing growth fueled by advanced product introductions and the rising incidence of infectious diseases.

Conversely, the Middle East & Africa is expected to be the least attractive market due to challenges such as a lack of skilled personnel and limited internet access for data analysis. However, price reductions and international collaborations may spur future growth in this region.

Unlocking the Potential of Immune Repertoire Sequencing

High-throughput sequencing of immunoglobulin and TCR sequences is opening up numerous opportunities for advancing our knowledge of human biology and medicine. Immune repertoire sequencing holds immense promise in biomarker discovery, vaccine development, and transplant selectivity. However, it also comes with its share of challenges, including the need for new sequenced databases, computational algorithms, and advanced software for comprehensive data analysis.

In conclusion, the ever-evolving field of immune repertoire sequencing is poised for continuous growth, driven by scientific breakthroughs in TCR and BCR repertoire research. These developments will serve as the foundation for new clinical applications in personalized medicine, providing deeper insights into the behavior and response of adaptive immunity.


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Immune Repertoire Sequencing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Immune Repertoire Sequencing Market Outlook, 2018 - 2031
3.1. Global Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Assay Kits
3.1.1.1.1. TCR Kits
3.1.1.1.2. BCR Kits
3.1.1.2. Software & Services
3.1.1.2.1. Analytical Software
3.1.1.2.2. Sequencing Services
3.1.1.2.3. Data Analysis Services
3.2. Global Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Biomarker Discovery
3.2.1.2. Infectious Diseases
3.2.1.3. Vaccine Development and efficacy
3.2.1.4. Cancer Immunotherapy
3.2.1.5. Autoimmune Disease
3.2.1.6. Transplant Rejection and Tolerance
3.2.1.7. Others
3.3. Global Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Academic Institutes
3.3.1.2. Research Centres
3.4. Global Immune Repertoire Sequencing Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Immune Repertoire Sequencing Market Outlook, 2018 - 2031
4.1. North America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Assay Kits
4.1.1.1.1. TCR Kits
4.1.1.1.2. BCR Kits
4.1.1.2. Software & Services
4.1.1.2.1. Analytical Software
4.1.1.2.2. Sequencing Services
4.1.1.2.3. Data Analysis Services
4.2. North America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Biomarker Discovery
4.2.1.2. Infectious Diseases
4.2.1.3. Vaccine Development and efficacy
4.2.1.4. Cancer Immunotherapy
4.2.1.5. Autoimmune Disease
4.2.1.6. Transplant Rejection and Tolerance
4.2.1.7. Others
4.3. North America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Academic Institutes
4.3.1.2. Research Centres
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Immune Repertoire Sequencing Market Outlook, 2018 - 2031
5.1. Europe Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Assay Kits
5.1.1.1.1. TCR Kits
5.1.1.1.2. BCR Kits
5.1.1.2. Software & Services
5.1.1.2.1. Analytical Software
5.1.1.2.2. Sequencing Services
5.1.1.2.3. Data Analysis Services
5.2. Europe Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Biomarker Discovery
5.2.1.2. Infectious Diseases
5.2.1.3. Vaccine Development and efficacy
5.2.1.4. Cancer Immunotherapy
5.2.1.5. Autoimmune Disease
5.2.1.6. Transplant Rejection and Tolerance
5.2.1.7. Others
5.3. Europe Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Academic Institutes
5.3.1.2. Research Centres
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.7. France Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.8. France Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.9. France Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest of Europe Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest of Europe Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest of Europe Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Immune Repertoire Sequencing Market Outlook, 2018 - 2031
6.1. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Assay Kits
6.1.1.1.1. TCR Kits
6.1.1.1.2. BCR Kits
6.1.1.2. Software & Services
6.1.1.2.1. Analytical Software
6.1.1.2.2. Sequencing Services
6.1.1.2.3. Data Analysis Services
6.2. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Biomarker Discovery
6.2.1.2. Infectious Diseases
6.2.1.3. Vaccine Development and efficacy
6.2.1.4. Cancer Immunotherapy
6.2.1.5. Autoimmune Disease
6.2.1.6. Transplant Rejection and Tolerance
6.2.1.7. Others
6.3. Asia Pacific Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Academic Institutes
6.3.1.2. Research Centres
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
6.4.1.2. China Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.3. China Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.10. India Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
6.4.1.11. India Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.12. India Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Immune Repertoire Sequencing Market Outlook, 2018 - 2031
7.1. Latin America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Assay Kits
7.1.1.1.1. TCR Kits
7.1.1.1.2. BCR Kits
7.1.1.2. Software & Services
7.1.1.2.1. Analytical Software
7.1.1.2.2. Sequencing Services
7.1.1.2.3. Data Analysis Services
7.2. Latin America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
7.2.1.1. Biomarker Discovery
7.2.1.2. Infectious Diseases
7.2.1.3. Vaccine Development and efficacy
7.2.1.4. Cancer Immunotherapy
7.2.1.5. Autoimmune Disease
7.2.1.6. Transplant Rejection and Tolerance
7.2.1.7. Others
7.3. Latin America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Academic Institutes
7.3.1.2. Research Centres
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest of Latin America Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest of Latin America Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest of Latin America Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Immune Repertoire Sequencing Market Outlook, 2018 - 2031
8.1. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Assay Kits
8.1.1.1.1. TCR Kits
8.1.1.1.2. BCR Kits
8.1.1.2. Software & Services
8.1.1.2.1. Analytical Software
8.1.1.2.2. Sequencing Services
8.1.1.2.3. Data Analysis Services
8.2. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Biomarker Discovery
8.2.1.2. Infectious Diseases
8.2.1.3. Vaccine Development and efficacy
8.2.1.4. Cancer Immunotherapy
8.2.1.5. Autoimmune Disease
8.2.1.6. Transplant Rejection and Tolerance
8.2.1.7. Others
8.3. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Academic Institutes
8.3.1.2. Research Centres
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heat map
9.2. Manufacturer vs by Application Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Illumina, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Pacific Biosciences of California, Inc
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Agilent Technologies, Inc
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Oxford Nanopore Technologies, Ltd
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. QIAGEN N.V.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Thermo Fisher Scientific
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. BGI
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Takara Bio, Inc
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. F. Hoffmann-La Roche Ltd
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Illumina, Inc.
  • Pacific Biosciences of California, Inc
  • Agilent Technologies, Inc
  • Oxford Nanopore Technologies, Ltd
  • QIAGEN N.V.
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • BGI
  • Takara Bio, Inc

Methodology

Loading
LOADING...